Assess whether a trial site should be referred (6cae9b)

Situation

Clinical-trial site anomaly report arrived with an AI RFP that treats accuracy as the only evaluation factor for IG improper-payments investigator. That is a US Federal AI Governance Vendor Risk decision on a trial site should be referred in an IG shop scoping a whistleblower allegation.

Decision

IG improper-payments investigator in an IG shop scoping a whistleblower allegation must choose Pursue / Pursue with conditions / Partner / No-bid using clinical-trial site anomaly report after an AI RFP that treats accuracy as the only evaluation factor.

Hypotheses to test

• An AI RFP that treats accuracy as the only evaluation factor is noise around an already-controlled AI Governance Vendor Risk process in an IG shop scoping a whistleblower allegation, given clinical-trial site anomaly report.
• An AI RFP that treats accuracy as the only evaluation factor is the event in clinical-trial site anomaly report that forces Pursue for IG improper-payments investigator under US Federal.
• Clinical-trial site anomaly report shows a one-file miss after an AI RFP that treats accuracy as the only evaluation factor, not a AI Governance Vendor Risk program failure.
• Clinical-trial site anomaly report cannot decide a trial site should be referred yet after an AI RFP that treats accuracy as the only evaluation factor; hold is the only US Federal close an IG shop scoping a whistleblower allegation can defend.

Analysis required

• Map FAR, Section L/M, and evaluator priorities in clinical-trial site anomaly report after an AI RFP that treats accuracy as the only evaluation factor.
• Name the evaluation right IG improper-payments investigator would forfeit by rushing.
• Normalize pricing and CPARS/QASP evidence that actually supports a trial site should be referred.
• For this US Federal AI Governance Vendor Risk file, read clinical-trial site anomaly report against an AI RFP that treats accuracy as the only evaluation factor and write the one fact that would move a trial site should be referred for IG improper-payments investigator.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / AI Governance Vendor Risk packet (clinical-trial site anomaly report after an AI RFP that treats accuracy as the only evaluation factor). The follow-on AI Governance Vendor Risk action is what IG improper-payments investigator does next: implement the option, assign an owner, and log the missing fact.